Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma

Overview

This is a prospective, open-labelled study to evaluate the efficacy and safety of camrelizumab combined with apatinib mesylate in the induction treatment of patients with locally advanced head and neck squamous cell carcinoma who were judged surgically unresectable or appropriate for non-surgical definitive therapy. The objective response rate (ORR) and safety will be evaluated as the primary endpoints, the 2-year overall survival (OS) rate and progression free survival (PFS) rate will be the second endpoints.

Full Title of Study: “Induction Therapy of Camrelizumab Combined With Apatinib Mesylate for Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (the IMplus Study)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 2022

Interventions

  • Drug: Camrelizumab
    • 200mg, iv, on day 1, 15, 29, 43
  • Drug: Apatinib Mesylate
    • 250 mg po, qd, 28 days as a cycle, 2 cycles in total

Arms, Groups and Cohorts

  • Experimental: Study group
    • Inductive therapy with Camrelizumab and Apatinib

Clinical Trial Outcome Measures

Primary Measures

  • Objective Response Rate (CR+PR)
    • Time Frame: 9 weeks
    • Objective Response Rate as defined by RECIST 1.1 after induction therapy followed by definitive chemoradiation. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Objective Response (OR) = CR + PR.

Secondary Measures

  • Number of Participants With at Least One Grade 3-4 Toxicity
    • Time Frame: 9 weeks
    • Toxicity will be assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4
  • Overall Survival
    • Time Frame: 2 years
    • Time to death or progression defined by imaging of target lesions via CT or MRI scan every 3 months
  • Progression-Free Survival
    • Time Frame: 2 years
    • Time to death or progression defined by imaging of target lesions via CT or MRI scan every 3 months

Participating in This Clinical Trial

Inclusion Criteria

1. Histologically or cytologically confirmed squamous cell or poorly differentiated or undifferentiated cancer of the head and neck (the primary sites include oral cavity, oropharynx, hypopharynx, larynx, nasal cavity and sinuses); 2. Clinical stage of III-IVb (AJCC 2018); 3. Surgically unresectable and/or refuse surgery or appropriate for non-surgical definitive therapy; 4. Measurable disease; 5. Eastern cooperative oncology group performance status (ECOG PS) score: 0-1; 6. Blood routine: white blood cells> 3,000/mm3, hemoglobin> 8g/L, platelets> 80,000/mm3;Liver function: Alanine Transaminase/Aspartate Transaminase <2.5 times the upper limit of normal, bilirubin <1.5 times the upper limit of normal; Renal function: serum creatinine <1.5 times the upper limit of normal; 7. Sign the informed consent. Exclusion Criteria:

1. Patients with poor-controlled arterial hypertension (systolic pressure ≥ 140 mmHg and/or diastolic pressure ≥ 90 mm Hg) despite standard medical management; 2. Suffered from grade II or above myocardial ischemia or myocardial infarction, uncontrolled arrhythmias (including QT interval male ≥ 450 ms, female ≥ 470 ms). Grade III-IV cardiac insufficiency according to New York Heart Association (NYHA) criteria or echocardiography check: left ventricular ejection fraction (LVEF)<50%; 3. Has had another active malignancy within the past five years except for cervical cancer in site, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin; 4. Clinically significant and uncontrolled major medical conditions including but not limited to: active uncontrolled infection, symptomatic congestive heart failure, Unstable angina pectoris or cardiac arrhythmia, psychiatric illness/ social situation that would limit compliance with study requirements; any medical condition, which in the opinion of the study investigator places the subject at an unacceptably high risk for toxicities; 5. Patients undergoing therapy with other investigational agents; 6. Women who are pregnant or breastfeeding; 7. Patients with any other concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for participation in the study.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Shanghai Ninth People’s Hospital Affiliated to Shanghai Jiao Tong University
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Guopei Zhu, M.D., 021-23271699, antica@gmail.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.